Erasca
Open
$10.37
Prev. Close
$10.37
High
$10.40
Low
$10.35
Market Snapshot
$2.58B
-20.8
-0.72
103
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Erasca (ERAS) reported a 0.5% daily increase, continuing a remarkable year-to-date gain of 176% in the biopharmaceutical sector focused on targeted cancer therapies.
Erasca, Inc. is a clinical stage precision oncology company. The company is headquartered in San Diego, California and currently employs 103 full-time employees. The company went IPO on 2021-07-15. The firm is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The firm has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Recently from Cashu
Clear Street Enhances Biotechnology Research Focus, Highlighting Erasca Investment Insights
Clear Street Expands Equity Research into Biotechnology Sector Clear Street, a cloud-native financial technology firm, is set to enhance its equity research capabilities by focusing on the healthcare…
Erasca: Taylor Swift's Eras Tour Redefines Engagement in the Entertainment Industry
Eras Tour: A Blueprint for Innovation in the Entertainment Industry Taylor Swift’s Eras Tour sets a new benchmark in the entertainment sector, accumulating over $2 billion in revenues over 21 months t…